Treatment's for Alzheimer's disease (AD) and cognitive decline is a health priority in our aging population. Compelling small scale studies suggest that elevated dietary, serum and brain levels of Advanced Glycation End products (AGEs), a group of glucose-derived compounds, contribute to cognitive impairment and increased brain pathology in old age. However, the scarcity of autopsy studies from large numbers of well- characterized older adults has made it difficult to obtain evidence linking brain AGEs with impaired cognition in older adults and whether brain AGEs mediate diet and serum AGEs with cognition. These gaps in knowledge impede the development of treatments based on AGEs to decrease the growing burden of AD and cognitive decline. To fill these gaps, the overall goal of this proposal is to test the hypothesis that brain AGEs are related to impaired cognition in older adults through an association with AD and other neuropathologies, and that dietary and serum AGEs are related to brain AGEs. To achieve these aims, we will enroll 700 community-dwelling older adults without clinical dementia from the Rush Memory and Aging Project (MAP, R01AG17911) who undergo annual testing and structured autopsy at death. This study proposes a comprehensive assessment of AGEs levels quantifying dietary, serum and brain AGEs levels. In addition, we will obtain and extract novel post-mortem brain MRI indices which complement available clinical data and traditional post-mortem brain histopathology. This comprehensive large-scale study will 1) provide evidence that brain AGEs levels are related to impaired cognition in older adults, 2) identify the key neuropathologies linking brain AGEs with cognition and 3) test if brain AGEs mediate the association of dietary and serum AGEs with cognition. These data are crucial for developing treatments targeting AGEs for late-life cognitive impairment. Thus, these data have the potential to decrease the growing burden of cognitive impairment and affect the brain health of millions of Americans in our aging population.

Public Health Relevance

A comprehensive assessment of dietary, serum and brain levels of Advanced Glycation End products (AGEs) in older adults will determine if AGEs are associated with Alzheimer's disease (AD), cognitive decline, and neuropathology. Identifying modifiable metabolites associated with impaired cognition, has potential to lead to new treatments that may decrease the growing burden of AD and impaired cognition in old age.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG053446-04
Application #
9741012
Study Section
Neurological, Aging and Musculoskeletal Epidemiology (NAME)
Program Officer
Anderson, Dallas
Project Start
2016-09-01
Project End
2022-05-31
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
4
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Psychiatry
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029